GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sprint Bioscience AB (OSTO:SPRINT) » Definitions » Cyclically Adjusted Price-to-FCF

Sprint Bioscience AB (OSTO:SPRINT) Cyclically Adjusted Price-to-FCF : (As of Jun. 19, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sprint Bioscience AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sprint Bioscience AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Sprint Bioscience AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sprint Bioscience AB Cyclically Adjusted Price-to-FCF Chart

Sprint Bioscience AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sprint Bioscience AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sprint Bioscience AB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Sprint Bioscience AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sprint Bioscience AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sprint Bioscience AB's Cyclically Adjusted Price-to-FCF falls into.



Sprint Bioscience AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Sprint Bioscience AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Sprint Bioscience AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.144/132.2054*132.2054
=-0.144

Current CPI (Mar. 2024) = 132.2054.

Sprint Bioscience AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.296 100.432 -0.390
201409 -0.530 100.161 -0.700
201412 -0.619 100.225 -0.817
201503 -0.533 99.950 -0.705
201506 -0.698 99.995 -0.923
201509 1.463 100.228 1.930
201512 -0.842 100.276 -1.110
201603 -0.787 100.751 -1.033
201606 -0.684 101.019 -0.895
201609 2.084 101.138 2.724
201612 -0.918 102.022 -1.190
201703 -0.966 102.022 -1.252
201706 -0.784 102.752 -1.009
201709 -0.476 103.279 -0.609
201712 -0.977 103.793 -1.244
201803 0.804 103.962 1.022
201806 -1.010 104.875 -1.273
201809 -1.055 105.679 -1.320
201812 -0.876 105.912 -1.093
201903 -1.078 105.886 -1.346
201906 -0.794 106.742 -0.983
201909 0.470 107.214 0.580
201912 -0.762 107.766 -0.935
202003 0.116 106.563 0.144
202006 -0.952 107.498 -1.171
202009 -0.566 107.635 -0.695
202012 -0.537 108.296 -0.656
202103 -0.537 108.360 -0.655
202106 -1.029 108.928 -1.249
202109 0.378 110.338 0.453
202112 -0.344 112.486 -0.404
202203 -0.343 114.825 -0.395
202206 -0.390 118.384 -0.436
202209 -0.369 122.296 -0.399
202212 0.000 126.365 0.000
202303 -0.032 127.042 -0.033
202306 -0.169 129.407 -0.173
202309 0.567 130.224 0.576
202312 -0.038 131.912 -0.038
202403 -0.144 132.205 -0.144

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sprint Bioscience AB  (OSTO:SPRINT) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Sprint Bioscience AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Sprint Bioscience AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sprint Bioscience AB (OSTO:SPRINT) Business Description

Traded in Other Exchanges
Address
Halsovagen 7, Floor 8, Elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a Sweden based company involved in developing drugs focused on cancer and metabolism. The project portfolio of the company includes STK25, VPS34, and PIP4K2.

Sprint Bioscience AB (OSTO:SPRINT) Headlines

No Headlines